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Abstract 
Objective  
The aim of this study was to investigate whether the classification of a previous 
spontaneous preterm birth (sPTB) into; i) sPTB or ii) PPROM, impacts the efficacy of 
cervical pessary or vaginal progesterone in pregnant women with short cervix on 
transvaginal ultrasound. 
Methods 
Four European hospitals using pessary or vaginal progesterone as a primary PTB 
prevention treatment for asymptomatic high-risk singletons with a short cervix, 
provided retrospective cohort data. A log-rank test on Kaplan-Meier curves assessed 
the difference in performance of pessary and progesterone depending on history of 
sPTB or PPROM. A linear regression analysis evaluated significant predictors of 
gestational age at delivery.  
Results 
Between 2008-2015, 170 women were treated with pessary and 88 with vaginal 
progesterone.  Rate of sPTB <34 weeks were 16% for ‘pessary + sPTB history’, 55% for 
pessary + PPROM history, 13% for ‘progesterone + sPTB history’ and  21% for 
‘progesterone + PPROM history’. Treatment with a pessary resulted in earlier delivery 
in women with previous PPROM than in any other subgroup; p=<0.0001 (p = 
1.45e−09). Linear regression showed clear effect of PPROM history (p=7.773e-10), an 
interaction of PPROM with treatment (p = 0.0002590) and effect of CL (p = 0.0003763) 
on gestation at birth. 
Conclusion  
Cervical pessary may be a less efficacious treatment option for women with previous 
PPROM, however results require prospective validation before change in practice is 
recommended. Phenotype of previous preterm births may be an important risk 
predictor and treatment effect modifier; this information should be reported in future 
clinical trials. 
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Introduction 
The presentation of preterm birth remains important for identifying the cause, 
estimating the risk of recurrence and implementing preventative strategies in 
subsequent pregnancies. A broad classification system of preterm birth based on 
presentation includes iatrogenic preterm birth, spontaneous preterm birth (sPTB) and 
preterm prelabor rupture of the membranes (PPROM) – each accounting for 
approximately one third of all preterm births.1  
More recently preterm birth classifications use an increasingly complex conceptual 
framework based on severe maternal, fetal, and placental conditions causally 
associated with preterm birth.2 Presently it is difficult to know how to apply this 
classification system to the management of subsequent pregnancy; many pregnancy 
observable characteristics fall across a minimum of two classifications and 
interventions for prevention remain limited. The only presentation for which there is 
effective intervention in singletons to prevent spontaneous preterm birth is a previous 
history of sPTB and/or a short cervix.3,4 
There is increasing evidence from systems biology (the computational and 
mathematical modeling of complex biological systems)  that sPTB(with intact 
membranes at labor,  sPTB) and PPROM have distinct biological pathways.5 An 
autoimmune/hormonal regulation axis may exist for sPTB, whilst pathways implicated 
in the etiology of PPROM include hematologic/coagulation function disorder, collagen 
metabolism, matrix degradation and local inflammation. Additionally, the dissimilarity 
of clinical risk factors for PPROM and sPTB suggest that there are different underlying 
pathophysiological pathways.6  
It is therefore reasonable to hypothesize that treatments for short cervix may exert 
different biological and environmental interactions and effects resulting in different 
pregnancy outcomes. Although exact mechanisms of action remains to be established, 
the action of vaginal progesterone and pessary are likely to be different mechanisms of 
therapeutic effect. The pessary is a device which provides mechanical support and 
increases the uterocervical angle at the cervix7 whereas vaginal progesterone has anti-
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inflammatory properties and inhibits production of stimulatory prostaglandins (PG) 
and expression of contraction associated protein genes in the myometrium. 8    
We investigated the success of vaginal progesterone and Arabin pessary based on the 
classification of previous spontaneous preterm pregnancies. Our aim was to compare 
the outcomes following both treatments in women who had previously experienced 
only sPTB compared to PPROM. 
Methods 
We identified four hospitals one in Liverpool, UK (Liverpool Women’s Hospital– LWH), 
two in Barcelona, Spain (Vall d’Hebron –VH; Hospital Clinic Barcelona – HCB) and one 
in Turin, Italy (Università degli Studi Torino – TOR) who have been using either cervical 
pessary ( a CE-certified pessary; CE 0482 / EN ISO 13485: 2003 annex III of the council 
directive 93/42 EEC ) or vaginal progesterone 200mg nocte as a primary treatment for 
preterm birth prevention between 2008 and 2015. We classified all women into two 
groups; a history of sPTB only ≤34 weeks or a history of PPROM ≤34 weeks. 
Classification was performed by preterm birth experts at each unit to classify these 
cases as correctly as possible. Any women who had pregnancies complicated with both 
sPTB and PPROM were included in the PPROM group. Our definition of PPROM for this 
study was a diagnosis of spontaneous rupture of the membranes at least 12 hours 
prior to delivery. We excluded all women with a history of a short cervix only (i.e. no 
history of preterm birth/PPROM), women treated prophylactically due to a history of 
sPTB or PPROM but no short cervix, cases where cervical length data were not 
available, multifetal pregnancies, congenital abnormalities diagnosed in the fetus and 
cases with cervical cerclage as a first line therapy. Short cervix was defined by 
individual hospital protocols but was either a single measurement of ≤25mm or less 
than 3rd centile for gestational age.9 Ethical approval was obtained at each hospital for 
use of patient data to be analyzed retrospectively.  
Our primary outcome was gestational age at delivery. For the primary analysis we 
excluded all women who had been additionally treated with a cervical cerclage or who 
had swapped treatment or added additional treatment based on a clinical perception 
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that the primary treatment was failing. A secondary analysis included all women based 
on an intention to treat principle.  
Statistical Methods 
Demographic data variables included in analysis were age, ethnicity, BMI, smoking, 
cervical surgery, number of term deliveries, number sPTB, number PPROM, GA earliest 
sPTB/PPROM and treatment for short cervix. IBM SPSS Statistics for Windows, Version 
22.0. (Armonk, NY: IBM Corp) was used to calculate P values using one-way ANOVA, 
Kruskal Wallis, Mann-Whitney U test, chi squared test or Fishers exact test as 
appropriate. Subsequently demographics were compared between women who had 
previously experienced sPTB only or PPROM. A log-rank test on Kaplan-Meier curves 
was performed to assess the difference in performance of VP and AP depending on 
history of sPTB or PPROM, using the software package R (https://cran.r-project.org/) In 
order to establish which clinical characteristics are significant predictors of gestation at 
delivery and by what magnitude they contribute to this pregnancy outcome we have 
also performed a linear regression analysis using  type of treatment, cervical length 
and phenotype of previous preterm birth as potential predictors.     
Results 
Data on 258 women with a history of PPROM or sPTB who had a subsequent 
treatment for short cervix with Arabin pessary or vaginal progesterone were obtained 
from four obstetric centers in Europe between 2008 and 2015 (Figure 1). Arabin 
pessary was the primary therapy in 170 women, 10 (6%) of whom required an 
additional therapy or change in treatment. Vaginal progesterone treatment was used 
in 88 cases and in 21 of them (24%) patients received an alternative or additive 
treatment following further cervical shortening. These 31 women with alternative or 
additive therapy were excluded from the primary analysis. Demographic data for the 
full cohort by centre and treatment group is included in supplementary table 1. The 
demographics for the remaining 227 women are shown by centre (table 1) and by 
treatment/history (table 2). Significant demographic differences between hospital 
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populations include tobacco use, cervical surgery and gestation at treatment with 
Turin centre screening until a later gestation than the other three hospitals (table 1), 
however there was no statistical significant difference in gestation at delivery by 
centre (p = 0.45). BMI was slightly lower in the ‘PPROM + Progesterone’ group with we 
felt that such a small difference, although statistically significant, would not be 
clinically important. Cervical surgery rates (24%) were also found to be higher in this 
group but this did not affect treatment performance measured by gestation at 
delivery. There was a significant increase in the number of women who had PPROM in 
their pregnancy if they had previously had PPROM compared to sPTB (32% versus 9%, 
P=<.001) (table 2). Overall women with a history of PPROM were more likely to deliver 
earlier than women with a history of sPTB (38 weeks versus 35 weeks, p = <.001). 
Using a log rank test on Kaplan-Meier survival curves, a four-way comparison was 
performed to assess if there was any difference in duration of pregnancy between 4 
distinct groups: i) previous PPROM treated with Arabin pessary; ii) previous sPTB- 
treated with Arabin pessary; iii) previous PPROM treated with vaginal progesterone; iv) 
previous sPTB treated with vaginal progesterone.  Overall, the difference between 4 
groups was highly significant (p<0.0001) due to much shorter gestation at delivery in 
women with previous PPROM treated with Arabin pessary. (Figure 2) When only 
women treated with progesterone were compared, there was no difference in the 
duration of pregnancy between women with previous PPROM and those with previous 
sPTB (p = 0.365).  The results remained qualitatively unchanged when 31 women who 
received combination treatment were included (intention to treat analysis, data 
included in Supplementary Figure 1). The median gestational age for women on vaginal 
progesterone (n=21 total; n=10 prev PPROM) who had additive or changed treatment 
was 38 weeks (range 18-41wks) compared to 27 weeks (range 19weeks – 38weeks) in 
the Arabin group (n=10 total; n=6 prev PPROM).  
We noted that the shortest cervical lengths at treatment were clustered in the Arabin 
+ PPROM group, with the median cervical length at treatment lower in this group by 3 
to 5mm (Table 2; p=0.021).  As shorter cervical length is a known risk factor for PTB we 
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performed a linear regression analysis to determine if cervical length affected both the 
allocation of group and outcome.  Our data confirmed that cervical length seems to be 
an independent predictor of gestation at birth (p=0.0003763), that is neither modified 
by nor modifying other factors. However, the strongest variables predicting earlier 
gestational age at delivery in our dataset were a history of PPROM (p=7.773e-10) and a 
combination of a history of PPROM and treatment (p = 0.0002590). Combining cervical 
length with treatment or PPROM history did not improve the prediction of gestational 
age at delivery.  
Discussion 
Analysis of data from this retrospective study have demonstrated that the previous 
observable characteristic of PPROM maybe an important predictor of the treatment 
success for short cervix in subsequent pregnancies. The Arabin pessary does not 
appear to have the same benefit in women who previously have experienced PPROM, 
compared to those with previous sPTB. Vaginal progesterone may, therefore, be a 
more efficacious treatment option for these women.  
The pathophysiological mechanism behind this effect is not clear. One possible theory 
is that the Arabin pessary may exacerbate a dysbiotic vaginal microbial environment. 
Kindinger et al. have looked at the effect suture material has on the vaginal 
environment for a similar at risk population. They demonstrated that, compared to a 
braided suture, a monofilament material reduced the risk of preterm birth by an 
additional 11% and also reduced rates of nonviable births (<24 weeks or intrauterine 
death).10 This causal effect was further supported by evidence that despite dysbiotic 
microbiomes being equal in prevalence prior to suture insertion, braided cerclage led 
to a shift towards dysbiosis in just 4 weeks after insertion. The Arabin pessary is a cone 
shaped silicone device that, once sited around a cervix, remains in the vagina until 
removal prior to labor. We hypothesize that similar effect could be involved here but 
found no published studies investigating an Arabin pessary’s possible impact on 
surrounding vaginal microbiome. One study examining ring pessaries for pelvic organ 
prolapse in a non-pregnant population demonstrated that they could exacerbate 
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growth of pre-existing anaerobic bacteria.11 The foreign body of the pessary could 
provide a surface for colonization, or alternatively many Arabin pessary users report a 
marked increase in watery discharge, which could affect vaginal microbial flora. In 
contrast, vaginal progesterone does not have any adverse impact on vaginal 
microbiota in pregnancy.12  
The effect of different outcomes in different populations may, at least in part, account 
for the variation that we have seen in recent years in the mixed outcomes of clinical 
trials of Arabin pessary for a short cervix. The landmark paper that brought Arabin 
pessary into more frequent use as an alternative to vaginal pessary and cervical 
cerclage in current clinical practice was the PECEP trial published in 2012 which 
reported a significant reduction in spontaneous delivery before 34 weeks of 
gestation.13 Mixed results have been reported in subsequent clinical trials of pessary 
for short cervix without satisfactory explanation.14-16 As most studies collect limited 
data on the observable characteristics of previous preterm births or any other 
biomarkers, further individual patient data analyses are unlikely to provide better 
evidence of the importance of various classifications of preterm labour as potential 
modifiers of treatment success.  
We acknowledge that our data are retrospective and therefore we cannot be certain 
that all classifications were assigned correctly. However, cases of sPTB and PPROM 
were reviewed by preterm birth experts at each unit to classify each case as correctly 
as possible. We would recommend the results of this study be validated in a separate 
population before advising a change in clinical practice. Our data is not randomized 
and therefore confounding as a cause of our results cannot be completely excluded.   
Although women in each group had a comparable distribution of cervical lengths, but 
the median measurement was lowest in the Arabin + PPROM group at 
17mm.However, a history of PPROM alone and PPROM interacting with treatment 
type were both independent predictors of gestational age at birth irrespective of 
cervical length when treatment was initiated. Whether in fact the pessary is 
exacerbating the risk of preterm birth in women with previous PPROM or alternatively 
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progesterone is modifying the risk from PPROM should be validated in future 
prospective studies.  
We did not explore the reasons that 10% of women given Arabin and 24% of women 
commenced on progesterone were given additional treatment, this may reflect 
ongoing shortening of the cervix, lack of faith in the treatment by the clinician or the 
patient or physical discomfort with treatment. The concern for the analysis was that 
patients requiring a second treatment may be at higher risk of delivering and bias our 
results by removing them, particularly as there are a greater percentage of the 
progesterone group. Our intention to treat analysis (including all cases) revealed 
irrespective of women changing or adding treatments, women with a history of 
PPROM who receive an Arabin pessary as first line treatment remain at increased risk 
of delivering earlier than women receiving vaginal progesterone (supplementary figure 1; 
p = 3e-09). 
Regrettably, we were unable to test in our data set whether the phenotype of previous 
preterm birth is also relevant for cervical cerclage. This may be potentially very 
important given that significant number of UK preterm birth prevention clinics still use 
cervical cerclage as a first line treatment for short cervix17  
The data from this study have fundamental implications for ongoing clinical trials into 
preterm birth treatments. We argue that data collection should take into account the 
observable characteristics of the previous preterm birth to allow sub classification of 
results based on previous history. In depth classifications have been published,2 but as 
a minimum trying to identify subgroups of sPTB and PPROM would be recommended. 
The authors acknowledge that the classification of PPROM can be particularly 
challenging given the subjectivity surrounding “the beginning of labor”, inability to 
access previous pregnancy details and poor note keeping.  Ideally, the phenotyping 
should also include other key features of the index pregnancy in addition to cervical 
length, including vaginal microbiome, quantitative fetal fibronectin and blood samples 
for biomarker testing (genomics, transcriptomics, proteomics etc.). Clearly, there are 
important implications on the design and size of future clinical trials if we expect to 
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test the effectiveness of ever smaller groups of patients, but better phenotyping 
would, as a minimum, encourage increased data sharing and much more informative 
and clinically useful individual patient data meta-analysis.  
Conclusion  
Arabin pessary may not be as effective in women who have previously experienced 
PPROM, compared to women with a history of sPTB. This differential effect is not seen 
with vaginal progesterone that may, therefore, be a better treatment choice for 
women with a history of PPROM and short cervix in pregnancy. This data suggests that 
it may be possible to stratify treatments for short cervix. We recommend data on 
previous pregnancy characteristics should be routinely collected as part of clinical trials 
of preterm birth prevention to evaluate this effect in other populations. 
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Table 1. Characteristics of women with previous sPTB/PPROM and short cervix by 
centre. 
 












Barcelona        
HCB  (n=20) 




Age, yrs* 31 (5) 31 (5) 33 (5) 32 (4) .514† 
BMI* 25 (5) 26 (3) 23 (5) 25 (4) .100† 
Ethnicity (% within centre) 
Caucasian  66 (85.7) 57(58.2) 18 (90) 28 (88) 
N/R 
Black  9 (11.7) 8 (8.2) 0 3 (9.4) 
Asian 1 (1.3) 10 (10.2) 0 0 
     
Indian 1 (1.3) 0 (0) 0 (0) 0 (0) 
Hispanic 0 23 (23.5) 2(10 0 (0) 
Tobacco Use, n (%) 26 (34) 21 (21) 4(20) 3 (9) .039‡ 
Cervical surgery, (%) 15  (19) 1 (1) 2 (10) 3 (9.4) <.001‡ 
Gestation at Rx, weeks
§
 21 (14-28) 22 (19-24) 23 (9-29) 25 (15-32) .001
¶
 




20 (3-29) 20 (5-25) 21 (9-24) 20 (0-27) .401
¶
 
Arabin pessary 38 98 0 24 N/R 
Vaginal progesterone 39 0 20 8 N/R 
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Table 2. Demographics and pregnancy outcomes for all 227 women included in 
primary analysis 






 Pessary (n= 160) Progesterone (n=67) P value 










Age, yrs* 31 (5) 32 (5) 31 (6) 32 (4) .745† 
BMI* 25 (4) 25 (4) 25 (4) 23 (5) .043† 
Ethnicity (%) 
Caucasian  92 (71) 17 (55) 33 (87) 27 (93) 
N/R 
Black  11 (9) 5 (16) 3 (8) 1 (3) 
Asian 4 (3) 6 (19) 0 1 (3) 
Indian 1 (1) 0 0 0 
Hispanic 21 (16) 3 (10) 2 (5) 0 
Tobacco Use, n (%) 31 (24) 5 (16) 10 (26) 8 (28) .712‡ 
Cervical surgery, n (%) 9 (7) 2 (7) 4 (11) 7 (24) .038‡ 
Gestation at Rx, wks § 22 (16-32) 22 (16-30) 22 (14-29) 22 (16-30) .941¶ 
Cervical Length at Rx 
(mm) § 
 
20 (3-29) 17 (4-27) 21 (6-27) 22 (0-26) .021¶ 
Pregnancy Outcomes 
Gestation at Delivery, 
w§ 
38 (22-41) 29 (21-40) 38 (27-41) 37 (23-41) <.001¶ 
PPROM, n (%) 11 (9) 10 (32) 4 (11) 9 (31) <.001‡ 
PTB < 34 weeks, n (%) 21 (16) 17 (55) 5 (13) 6 (21) <.001‡ 
CS, n (%) 20 (16) 5 (16) 5 (13) 7 (24) .650‡ 
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Figure Legends 
Figure 1. Flow diagram of cases included. 
Figure 2. Survival curves demonstrating preterm birth probabilities by obstetric history and 
treatment group in primary analysis (n=227) 
Supplementary Table 1 Demographics and pregnancy outcomes for all 258 women included in 
intention to treat analysis 
Supplementary Figure 1 Survival curves demonstrating preterm birth probabilities by obstetric 








































Screened patient cases attending specialist preterm birth 
prevention clinics: n= 3,325 
 
Total number of cases identified for analysis; n = 258  
Previous sPTB-IM: 167 Previous PPROM: 60 
2,086 did not require treatment for short 
cervix   
930 did not have history of previous preterm 
birth or PPROM  
12 Multiple pregnancy  
36 had treatment with cerclage as primary 
treatment.  
3 no delivery details recorded  
Total number of cases included in primary analysis; n = 227 
31 women changed or received additional 
treatments (secondary analysis only) 
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